<?xml version='1.0' encoding='utf-8'?>
<document id="31341258"><sentence text="Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2."><entity charOffset="0-11" id="DDI-PubMed.31341258.s1.e0" text="Leflunomide" /><entity charOffset="44-53" id="DDI-PubMed.31341258.s1.e1" text="acyclovir" /><pair ddi="false" e1="DDI-PubMed.31341258.s1.e0" e2="DDI-PubMed.31341258.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s1.e0" e2="DDI-PubMed.31341258.s1.e1" /></sentence><sentence text="Rheumatoid arthritis patients can be prescribed a combination of immunosuppressive drug leflunomide (LEF) and the antiviral drug acyclovir to reduce the high risk of infection"><entity charOffset="88-99" id="DDI-PubMed.31341258.s2.e0" text="leflunomide" /><entity charOffset="101-104" id="DDI-PubMed.31341258.s2.e1" text="LEF" /><entity charOffset="129-138" id="DDI-PubMed.31341258.s2.e2" text="acyclovir" /><pair ddi="false" e1="DDI-PubMed.31341258.s2.e0" e2="DDI-PubMed.31341258.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s2.e0" e2="DDI-PubMed.31341258.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s2.e0" e2="DDI-PubMed.31341258.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s2.e1" e2="DDI-PubMed.31341258.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s2.e1" e2="DDI-PubMed.31341258.s2.e2" /></sentence><sentence text=" Acyclovir is a substrate of organic anion transporter (OAT) 1/3 and multidrug resistance-associated protein (MRP) 2"><entity charOffset="1-10" id="DDI-PubMed.31341258.s3.e0" text="Acyclovir" /></sentence><sentence text=" Considering the extraordinarily long half-life of LEF's active metabolite teriflunomide (TER) and the kidney injury risk of acyclovir, it is necessary to elucidate the potential impact of LEF on the disposition of acyclovir"><entity charOffset="75-88" id="DDI-PubMed.31341258.s4.e0" text="teriflunomide" /><entity charOffset="90-93" id="DDI-PubMed.31341258.s4.e1" text="TER" /><entity charOffset="125-134" id="DDI-PubMed.31341258.s4.e2" text="acyclovir" /><entity charOffset="215-224" id="DDI-PubMed.31341258.s4.e3" text="acyclovir" /><entity charOffset="51-59" id="DDI-PubMed.31341258.s4.e4" text="LEF" /><entity charOffset="189-197" id="DDI-PubMed.31341258.s4.e5" text="LEF" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e4" e2="DDI-PubMed.31341258.s4.e4" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e4" e2="DDI-PubMed.31341258.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e4" e2="DDI-PubMed.31341258.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e4" e2="DDI-PubMed.31341258.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e4" e2="DDI-PubMed.31341258.s4.e5" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e4" e2="DDI-PubMed.31341258.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e0" e2="DDI-PubMed.31341258.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e0" e2="DDI-PubMed.31341258.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e0" e2="DDI-PubMed.31341258.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e0" e2="DDI-PubMed.31341258.s4.e5" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e0" e2="DDI-PubMed.31341258.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e1" e2="DDI-PubMed.31341258.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e1" e2="DDI-PubMed.31341258.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e1" e2="DDI-PubMed.31341258.s4.e5" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e1" e2="DDI-PubMed.31341258.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e2" e2="DDI-PubMed.31341258.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e2" e2="DDI-PubMed.31341258.s4.e5" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e2" e2="DDI-PubMed.31341258.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e5" e2="DDI-PubMed.31341258.s4.e5" /><pair ddi="false" e1="DDI-PubMed.31341258.s4.e5" e2="DDI-PubMed.31341258.s4.e3" /></sentence><sentence text=" Here we used a specific MRP inhibitor MK571 and probenecid (OAT1/3 and MRP2 inhibitor) to assess the effects of MRP2 and OAT1/3 on the pharmacokinetics and tissue distribution of acyclovir in rats"><entity charOffset="180-189" id="DDI-PubMed.31341258.s5.e0" text="acyclovir" /></sentence><sentence text=" We showed that LEF and probenecid, but not MK571 significantly increased the plasma concentration of acyclovir"><entity charOffset="24-34" id="DDI-PubMed.31341258.s6.e0" text="probenecid" /><entity charOffset="102-111" id="DDI-PubMed.31341258.s6.e1" text="acyclovir" /><entity charOffset="16-24" id="DDI-PubMed.31341258.s6.e2" text="LEF" /><pair ddi="false" e1="DDI-PubMed.31341258.s6.e2" e2="DDI-PubMed.31341258.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s6.e2" e2="DDI-PubMed.31341258.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s6.e2" e2="DDI-PubMed.31341258.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s6.e0" e2="DDI-PubMed.31341258.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s6.e0" e2="DDI-PubMed.31341258.s6.e1" /></sentence><sentence text=" However, kidney and liver exposures of acyclovir were increased when coadministered with LEF, probenecid or MK571"><entity charOffset="40-49" id="DDI-PubMed.31341258.s7.e0" text="acyclovir" /><entity charOffset="90-93" id="DDI-PubMed.31341258.s7.e1" text="LEF" /><entity charOffset="95-105" id="DDI-PubMed.31341258.s7.e2" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.31341258.s7.e0" e2="DDI-PubMed.31341258.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s7.e0" e2="DDI-PubMed.31341258.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s7.e0" e2="DDI-PubMed.31341258.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s7.e1" e2="DDI-PubMed.31341258.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s7.e1" e2="DDI-PubMed.31341258.s7.e2" /></sentence><sentence text=" The kidney/plasma ratio of acyclovir was increased to approximately 2-fold by LEF or probenecid, whereas it was increased to as much as 14"><entity charOffset="28-37" id="DDI-PubMed.31341258.s8.e0" text="acyclovir" /><entity charOffset="86-96" id="DDI-PubMed.31341258.s8.e1" text="probenecid" /><entity charOffset="79-88" id="DDI-PubMed.31341258.s8.e2" text="LEF" /><pair ddi="false" e1="DDI-PubMed.31341258.s8.e0" e2="DDI-PubMed.31341258.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s8.e0" e2="DDI-PubMed.31341258.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s8.e0" e2="DDI-PubMed.31341258.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s8.e2" e2="DDI-PubMed.31341258.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s8.e2" e2="DDI-PubMed.31341258.s8.e1" /></sentence><sentence text="5-fold by MK571" /><sentence text=" Consistently, these drugs markedly decreased the urinary excretion of acyclovir"><entity charOffset="71-80" id="DDI-PubMed.31341258.s10.e0" text="acyclovir" /></sentence><sentence text=" TER (0"><entity charOffset="1-9" id="DDI-PubMed.31341258.s11.e0" text="TER" /></sentence><sentence text="5-100 μmol/L) dose-dependently increased the accumulation of acyclovir in MRP2-MDCK cells with an IC50 value of 4"><entity charOffset="61-70" id="DDI-PubMed.31341258.s12.e0" text="acyclovir" /></sentence><sentence text="91 μmol/L" /><sentence text=" TER (5 μmol/L) significantly inhibited the uptake of acyclovir in hOAT1/3-HEK293 cells"><entity charOffset="54-63" id="DDI-PubMed.31341258.s14.e0" text="acyclovir" /><entity charOffset="1-9" id="DDI-PubMed.31341258.s14.e1" text="TER" /><pair ddi="false" e1="DDI-PubMed.31341258.s14.e1" e2="DDI-PubMed.31341258.s14.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s14.e1" e2="DDI-PubMed.31341258.s14.e0" /></sentence><sentence text=" These results suggest that LEF/TER increased the kidney accumulation of acyclovir by inhibiting the efflux transporter MRP2, which increased its kidney/plasma ratio and renal injury risk"><entity charOffset="73-82" id="DDI-PubMed.31341258.s15.e0" text="acyclovir" /><entity charOffset="28-36" id="DDI-PubMed.31341258.s15.e1" text="LEF" /><entity charOffset="32-40" id="DDI-PubMed.31341258.s15.e2" text="TER" /><pair ddi="false" e1="DDI-PubMed.31341258.s15.e1" e2="DDI-PubMed.31341258.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s15.e1" e2="DDI-PubMed.31341258.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s15.e1" e2="DDI-PubMed.31341258.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s15.e2" e2="DDI-PubMed.31341258.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s15.e2" e2="DDI-PubMed.31341258.s15.e0" /></sentence><sentence text=" However, the inhibitory effects of LEF/TER on OAT1/3 reduced the tubular cells' uptake of acyclovir and increased the plasma concentration"><entity charOffset="91-100" id="DDI-PubMed.31341258.s16.e0" text="acyclovir" /><entity charOffset="36-44" id="DDI-PubMed.31341258.s16.e1" text="LEF" /><entity charOffset="40-48" id="DDI-PubMed.31341258.s16.e2" text="TER" /><pair ddi="false" e1="DDI-PubMed.31341258.s16.e1" e2="DDI-PubMed.31341258.s16.e1" /><pair ddi="false" e1="DDI-PubMed.31341258.s16.e1" e2="DDI-PubMed.31341258.s16.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s16.e1" e2="DDI-PubMed.31341258.s16.e0" /><pair ddi="false" e1="DDI-PubMed.31341258.s16.e2" e2="DDI-PubMed.31341258.s16.e2" /><pair ddi="false" e1="DDI-PubMed.31341258.s16.e2" e2="DDI-PubMed.31341258.s16.e0" /></sentence><sentence text="" /></document>